Dovitinib
Dovitinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against receptor-type tyrosine-protein kinase FLT3. In addition, it is known to target fibroblast growth factor receptor 1, macrophage colony-stimulating factor 1 receptor, vascular endothelial growth factor receptor 1, mast/stem cell growth factor receptor Kit, vascular endothelial growth factor receptor 3, epidermal growth factor receptor, fibroblast growth factor receptor 3, platelet-derived growth factor receptor beta, vascular endothelial growth factor receptor 2, platelet-derived growth factor receptor alpha, and insulin receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
59 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 11 | 3 | 1 | — | — | 14 |
| Carcinoma | D002277 | — | C80.0 | — | 6 | 1 | — | — | 7 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 2 | 1 | 1 | — | — | 4 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 4 | 4 | — | — | — | 7 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 2 | 3 | — | — | — | 4 |
| Multiple myeloma | D009101 | — | C90.0 | 2 | 1 | — | — | — | 3 |
| Colorectal neoplasms | D015179 | — | — | 1 | 2 | — | — | — | 3 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 1 | — | — | — | 3 |
| Recurrence | D012008 | — | — | 1 | 1 | — | — | — | 2 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | 1 | — | — | — | 2 |
| Prostatic neoplasms | D011471 | — | C61 | — | 2 | — | — | — | 2 |
| Urinary bladder neoplasms | D001749 | — | C67 | 1 | 1 | — | — | — | 2 |
| Transitional cell carcinoma | D002295 | — | — | — | 2 | — | — | — | 2 |
Show 21 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | 1 | — | — | — | — | 1 |
| Pancreatic ductal carcinoma | D021441 | — | — | 1 | — | — | — | — | 1 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
| Leukemia | D007938 | — | C95 | 1 | — | — | — | — | 1 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | — | — | — | 1 |
| Myeloid leukemia | D007951 | — | C92 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Dovitinib |
| INN | dovitinib |
| Description | 4-amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1,3-dihydrobenzimidazol-2-ylidene]-2-quinolinone is a N-arylpiperazine. |
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 1027263-12-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL522892 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | I35H55G906 (ChemIDplus, GSRS) |
Target
Agency Approved
FLT3
FLT3
Organism
Homo sapiens
Gene name
FLT3
Gene synonyms
CD135, FLK2, STK1
NCBI Gene ID
Protein name
receptor-type tyrosine-protein kinase FLT3
Protein synonyms
CD135, CD135 antigen, fetal liver kinase 2, Fetal liver kinase-2, FL cytokine receptor, FLK-2, FLT-3, fms related tyrosine kinase 3, Fms-like tyrosine kinase 3, growth factor receptor tyrosine kinase type III, Stem cell tyrosine kinase 1, STK-1
Uniprot ID
Mouse ortholog
Flt3 (14255)
receptor-type tyrosine-protein kinase FLT3 (Q00342)
Alternate
FGFR1
FGFR1
CSF1R
CSF1R
FLT1
FLT1
KIT
KIT
FLT4
FLT4
EGFR
EGFR
FGFR3
FGFR3
PDGFRB
PDGFRB
KDR
KDR
PDGFRA
PDGFRA
INSR
INSR
Organism
Homo sapiens
Gene name
FGFR1
Gene synonyms
BFGFR, CEK, FGFBR, FLG, FLT2, HBGFR
NCBI Gene ID
Protein name
fibroblast growth factor receptor 1
Protein synonyms
Basic fibroblast growth factor receptor 1, bFGF-R-1, BFGFR, CD331, FGFR1/PLAG1 fusion, FLT-2, FMS-like tyrosine kinase 2, fms-related tyrosine kinase 2, heparin-binding growth factor receptor, hydroxyaryl-protein kinase, N-sam, Proto-oncogene c-Fgr
Uniprot ID
Mouse ortholog
Fgfr1 (14182)
fibroblast growth factor receptor 1 (Q9QZM7)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,174 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
50 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use